VistaGen Therapeutics, Inc. (VTGN)
Company Description
Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders.
The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.
Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder.
In addition, the company is also developing PH15, an early-stage investigational synthetic neuroactive steroid for the treatment of cognition improvement; PH80, an odorless and tasteless synthetic investigational pherine for the treatment of menopausal hot flashes and migraine; PH284, an early-stage investigational synthetic neuroactive steroid for the treatment of wasting syndrome Cachexia; and AV-101, an oral nmdr glycine site antagonist for depression and neurological disorders.
Further, it has a license and collaboration agreement with EverInsight Therapeutics Inc. to develop and commercialize to address ophthalmologic and CNS disorders.
The company was founded in 1998 and is headquartered in South San Francisco, California.
Country | United States |
Founded | 1998 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 37 |
CEO | Shawn K. Singh J.D. |
Contact Details
Address: 343 Allerton Avenue South San Francisco, California 94080 United States | |
Phone | 650-577-3600 |
Website | vistagen.com |
Stock Details
Ticker Symbol | VTGN |
Exchange | NASDAQ |
Fiscal Year | April - March |
Reporting Currency | USD |
CIK Code | 0001411685 |
CUSIP Number | 92840H202 |
ISIN Number | US92840H4002 |
Employer ID | 20-5093315 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Shawn K. Singh J.D. | Chief Executive Officer and Director |
Reid G. Adler Esq., J.D. | Chief Corporate Development Officer and General Counsel |
Cynthia Lynn Anderson CPA | Chief Financial Officer |
Joshua Prince M.B.A. | Chief Operating Officer |
Mark Adrian McPartland | Senior Vice President of Investor Relations |
Trisha Fitzmaurice | Senior Vice President of Human Resources |
Dr. Allen Easley Cato III, M.D., Ph.D. | Senior Vice President of Development Operations |
Dr. Mark J. Ginski Ph.D. | Senior Vice President and Head of Chemistry, Manufacturing and Controls |
Mark Flather | Senior Vice President of Corporate Strategy and Capital Markets |
Dr. Erik Berglund M.D., Ph.D. | Senior Vice President of Global Regulatory Affairs and Pharmacovigilance |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Feb 29, 2024 | EFFECT | Notice of Effectiveness |
Feb 16, 2024 | UPLOAD | Filing |
Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Feb 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Feb 13, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
Feb 13, 2024 | S-3 | Registration statement under Securities Act of 1933 |
Feb 13, 2024 | 8-K | Current Report |
Feb 13, 2024 | 10-Q | Quarterly Report |